Exemplar Genetics

exemplargenetics.com

At Exemplar Genetics, we enable discovery by providing the vehicle to break new ground on the medical research frontier. Until now, researchers have lacked animal models that faithfully represent human diseases. As a result, a sizeable barrier has blocked progress in the discovery of human disease mechanisms; novel diagnostics, procedures, devices, prevention strategies and therapeutics; and the ability to predict in humans the efficacy of those next-generation procedures, devices, and therapeutics.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

MEDICAL, INDUSTRY OUTLOOK

BAYER AND BICYCLE THERAPEUTICS ENTER STRATEGIC COLLABORATION FOR DEVELOPMENT OF NOVEL TARGETED RADIONUCLIDE THERAPIES IN ONCOLOGY

Businesswire | May 11, 2023

news image

Bayer and Bicycle Therapeutics plc a biotechnology company pioneering a new and differentiated class of therapeutics by utilizing proprietary bicyclic peptides technology (Bicycle®), announced that they have entered into a strategic collaboration agreement to discover, develop, manufacture, and commercialize Bicycle radioconjugates for multiple agreed upon oncology targets. Bicyclic peptides are peptides consisting of 9-20 amino acids that can be synthetically manufactured a...

Read More

PHARMACYTE BIOTECH ANNOUNCES IND SUBMITTED TO U.S. FDA FOR CLINICAL TRIAL IN LOCALLY ADVANCED, INOPERABLE PANCREATIC CANCER

PharmaCyte Biotech | September 02, 2020

news image

PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical-stage biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that it has submitted an Investigational New Drug application (IND) to the U.S. Food and Drug Administration (FDA) for a planned Phase 2b clinical trial in locally advanced, inoperable pancreatic cancer (LAPC). PharmaCyte’s Chief Executive Officer, Kenneth L...

Read More

MEDTECH

SYNTHEGO LAUNCHES ENGINEERED CELL LIBRARIES TO VALIDATE TARGETS WITH SPEED AND ACCELERATE DRUG DISCOVERY

SYNTHEGO | August 03, 2022

news image

Synthego, the genome engineering company, announced the launch of Engineered Cell Libraries, a novel offering that further enables access to CRISPR by providing arrayed CRISPR-edited cells for direct use in functional screening assays. The innovative solution leverages Synthego’s Eclipse™ Platform. This high-throughput cell engineering platform delivers cell-based models for disease research by providing highly predictable CRISPR-engineered cells at scale through the integration of e...

Read More

INDUSTRIAL IMPACT

PORTAL INNOVATIONS EXPANDS CHICAGO OPERATIONS TRIPLES SPACE IN FULTON LABS

Portal Innovations | February 03, 2022

news image

Portal Innovations continues its momentum in Chicago by launching the second phase of its operations with the opening of 35,000 square feet of premier wet and dry lab and office space at 400 North Aberdeen in Fulton Labs. The new facility will allow Portal, a life sciences venture development engine, to grow and scale its investment in early-stage biotech companies in Chicago. Portal has tapped Patrick Flavin to serve as President of its flagship Chicago operation. With over 20 ye...

Read More
news image

MEDICAL, INDUSTRY OUTLOOK

BAYER AND BICYCLE THERAPEUTICS ENTER STRATEGIC COLLABORATION FOR DEVELOPMENT OF NOVEL TARGETED RADIONUCLIDE THERAPIES IN ONCOLOGY

Businesswire | May 11, 2023

Bayer and Bicycle Therapeutics plc a biotechnology company pioneering a new and differentiated class of therapeutics by utilizing proprietary bicyclic peptides technology (Bicycle®), announced that they have entered into a strategic collaboration agreement to discover, develop, manufacture, and commercialize Bicycle radioconjugates for multiple agreed upon oncology targets. Bicyclic peptides are peptides consisting of 9-20 amino acids that can be synthetically manufactured a...

Read More
news image

PHARMACYTE BIOTECH ANNOUNCES IND SUBMITTED TO U.S. FDA FOR CLINICAL TRIAL IN LOCALLY ADVANCED, INOPERABLE PANCREATIC CANCER

PharmaCyte Biotech | September 02, 2020

PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical-stage biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that it has submitted an Investigational New Drug application (IND) to the U.S. Food and Drug Administration (FDA) for a planned Phase 2b clinical trial in locally advanced, inoperable pancreatic cancer (LAPC). PharmaCyte’s Chief Executive Officer, Kenneth L...

Read More
news image

MEDTECH

SYNTHEGO LAUNCHES ENGINEERED CELL LIBRARIES TO VALIDATE TARGETS WITH SPEED AND ACCELERATE DRUG DISCOVERY

SYNTHEGO | August 03, 2022

Synthego, the genome engineering company, announced the launch of Engineered Cell Libraries, a novel offering that further enables access to CRISPR by providing arrayed CRISPR-edited cells for direct use in functional screening assays. The innovative solution leverages Synthego’s Eclipse™ Platform. This high-throughput cell engineering platform delivers cell-based models for disease research by providing highly predictable CRISPR-engineered cells at scale through the integration of e...

Read More
news image

INDUSTRIAL IMPACT

PORTAL INNOVATIONS EXPANDS CHICAGO OPERATIONS TRIPLES SPACE IN FULTON LABS

Portal Innovations | February 03, 2022

Portal Innovations continues its momentum in Chicago by launching the second phase of its operations with the opening of 35,000 square feet of premier wet and dry lab and office space at 400 North Aberdeen in Fulton Labs. The new facility will allow Portal, a life sciences venture development engine, to grow and scale its investment in early-stage biotech companies in Chicago. Portal has tapped Patrick Flavin to serve as President of its flagship Chicago operation. With over 20 ye...

Read More